drugset / Trial / NCT00507247
Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus
Phase 2
Completed
11 enrolled
M.D. Anderson Cancer Center
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · collab
NaSingle-groupOpen-labelTreatment
Summary
Primary Objective: Evaluate the efficacy and safety of daptomycin given for treatment of catheter-related bloodstream infections due to S. aureus bacteria with or without exchange of the central venous catheter (CVC) over guide wire in comparison with a historical control group of catheter-related S. aureus bacteremia treated with standard therapy (Vancomycin) or other active agents against staph aureus (such as beta-lactam antibiotics).
Timeline
- Start
- 2006-05
- Primary completion
- 2007-10
- Completion
- 2012-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daptomycin | Other / unclassified | 6 mg/kg | Intravenous |